CoChat
Sign Up
Cited by 92

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Matrix metalloproteinases in Alzheimer’s disease and concurrent cerebral microbleeds.

Duits, Flora H., Hernandez-Guillamon, Mar, Montaner, Joan, Goos, Jereon D.C., Montañola, Alex, Wattjes, Mike P., Barkhof, Frederik, Scheltens, Philip, Teunissen, Charlotte E., van der Flier, Wiesje M.·2015·Journal of Alzheimer's Disease
DOI 10.3233/jad-143186
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-143186

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 41

  1. Blennow, 2006, Alzheimer’s disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7 · DOI · Paper page
  2. Knudsen, 2001, Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston criteria, Neurology, 56, 537, 10.1212/WNL.56.4.537 · DOI · Paper page
  3. Attems, 2005, Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy, Acta Neuropathol, 110, 222, 10.1007/s00401-005-1064-y · DOI · Paper page
  4. Cordonnier, 2011, Brain microbleeds and Alzheimer’s disease: Innocent observation or key player?, Brain, 134, 335, 10.1093/brain/awq321 · DOI · Paper page
  5. Goos, 2012, Microbleeds relate to altered amyloid-beta metabolism in Alzheimer’s disease, Neurobiol Aging, 33, 1011, 10.1016/j.neurobiolaging.2011.10.026 · DOI
  6. Yong, 2001, Metalloproteinases in biology and pathology of the nervous system, Nat Rev Neurosci, 2, 502, 10.1038/35081571 · DOI
  7. Wisniewski, 1997, Amyloid angiopathy and blood-brain barrier changes in Alzheimer’s disease, Ann N Y Acad Sci, 826, 161, 10.1111/j.1749-6632.1997.tb48468.x · DOI
  8. Farrall, 2009, Blood-brain barrier: Ageing and microvascular disease–systematic review and meta-analysis, Neurobiol Aging, 30, 337, 10.1016/j.neurobiolaging.2007.07.015 · DOI · Paper page
  9. Cuadrado, 2009, Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: A combined laser microdissection and protein array study, J Proteome Res, 8, 3191, 10.1021/pr801012x · DOI
  10. Hernandez-Guillamon, 2009, Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25–35 fragment, J Neurosci Res, 87, 2115, 10.1002/jnr.22034 · DOI · Paper page
  11. Konnecke, 2013, The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas, Clin Dev Immunol, 2013, 914104, 10.1155/2013/914104 · DOI
  12. Deb, 1996, Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides, J Neurochem, 66, 1641, 10.1046/j.1471-4159.1996.66041641.x · DOI
  13. Lee, 2003, Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy, Ann Neurol, 54, 379, 10.1002/ana.10671 · DOI
  14. Hernandez-Guillamon, 2012, MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke, Brain Pathol, 22, 133, 10.1111/j.1750-3639.2011.00512.x · DOI
  15. Lorenzl, 2003, Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease, Neurochem Int, 43, 191, 10.1016/S0197-0186(03)00004-4 · DOI · Paper page
  16. Adair, 2004, Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease, Stroke, 35, e159, 10.1161/01.STR.0000127420.10990.76 · DOI
  17. Mlekusch, 2009, Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels, Neurosci Lett, 466, 135, 10.1016/j.neulet.2009.09.043 · DOI
  18. Martin-Aragon, 2009, Metalloproteinase’s activity and oxidative stress in mild cognitive impairment and Alzheimer’s disease, Neurochem Res, 34, 373, 10.1007/s11064-008-9789-3 · DOI
  19. Horstmann, 2010, Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer’s disease, Int Psychogeriatr, 22, 966, 10.1017/S1041610210000827 · DOI
  20. Bjerke, 2011, Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease, J Alzheimers Dis, 27, 665, 10.3233/JAD-2011-110566 · DOI · Paper page
  21. Lim, 2011, Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer’s disease, J Alzheimers Dis, 26, 779, 10.3233/JAD-2011-101974 · DOI
  22. van der Flier, 2014, Optimizing patient care and research: The Amsterdam Dementia Cohort, J Alzheimers Dis, 41, 313, 10.3233/JAD-132306 · DOI
  23. van der, 2009, CSF biomarkers in relationship to cognitive profiles in Alzheimer disease, Neurology, 72, 1056, 10.1212/01.wnl.0000345014.48839.71 · DOI
  24. McKhann, 2011, The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 263, 10.1016/j.jalz.2011.03.005 · DOI · Paper page
  25. Roman, 1993, Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop, Neurology, 43, 250, 10.1212/WNL.43.2.250 · DOI · Paper page
  26. Jongbloed, 2013, Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study, Alzheimers Dement, 9, 276, 10.1016/j.jalz.2012.01.004 · DOI
  27. Goos, 2011, Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging, Stroke, 42, 1894, 10.1161/STROKEAHA.110.599837 · DOI
  28. Benedictus, 2013, Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer’s disease, Neurobiol Aging, 34, 2488, 10.1016/j.neurobiolaging.2013.04.023 · DOI
  29. Fazekas, 1987, MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging, AJR Am J Roentgenol, 149, 351, 10.2214/ajr.149.2.351 · DOI
  30. Scheltens, 1995, Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability, J Neurol, 242, 557
  31. Pasquier, 1996, Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts, Eur Neurol, 36, 268, 10.1159/000117270 · DOI
  32. Yates, 2014, Cerebral microbleeds: A review of clinical, genetic, and neuroimaging associations, Front Neurol, 4, 205, 10.3389/fneur.2013.00205 · DOI
  33. Yin, 2006, Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism, J Neurosci, 26, 10939, 10.1523/JNEUROSCI.2085-06.2006 · DOI · Paper page
  34. Murray, 2013, Macrophage migration and invasion is regulated by MMP10 expression, PLoS One, 8, e63555, 10.1371/journal.pone.0063555 · DOI
  35. Craig-Schapiro, 2011, Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis, PLoS One, 6, e18850, 10.1371/journal.pone.0018850 · DOI
  36. Nuttall, 2007, Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia, Glia, 55, 516, 10.1002/glia.20478 · DOI
  37. Lorenzl, 2003, Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases, J Neurol Sci, 207, 71, 10.1016/S0022-510X(02)00398-2 · DOI
  38. Hartz, 2012, Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy, Stroke, 43, 514, 10.1161/STROKEAHA.111.627562 · DOI · Paper page
  39. van de Haar, 2015, Blood-brain barrier impairment in dementia: Current and future in vivo assessments, Neurosci Biobehav Rev, 49, 71, 10.1016/j.neubiorev.2014.11.022 · DOI
  40. Rouy, 2005, Plasma storage at −80 degrees C does not protect matrix metalloproteinase-9 from degradation, Anal Biochem, 338, 294, 10.1016/j.ab.2004.10.052 · DOI
  41. Tarr, 2011, Seasonal variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor of matrix metalloproteinase-1 with storage at −80 degrees C, Clin Biochem, 44, 1346, 10.1016/j.clinbiochem.2011.08.1139 · DOI

Cited by

Sorted by citations

Metadata

Authors
Duits, F. H., Hernandez-Guillamon, M., Montaner, J., Goos, J. D. C., Montañola, A., Wattjes, M. P., Barkhof, F., Scheltens, P., Teunissen, C. E., & van der Flier, W. M.
Affiliations
  • Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
  • Neurovascular Research Laboratory, Institut de Recerca, Barcelona, Spain
  • Department of Radiology & Nuclear Medicine, Neuroscience Campus Amsterdam,VU University Medical Center, Amsterdam, The Netherlands
  • Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
Venue
Journal of Alzheimer's Disease
Publisher
SAGE Publications
Published
2015-10-01
Volume
48
Issue
3
Pages
711-720
ISSN
  • 1387-2877
  • 1875-8908
DOI
10.3233/jad-143186
Cited by
92
References
7

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review